Illumina launches warning, Colgate-Palmolive makes an acquisition

Tonight announces itself as an animated session – and for some lucrative – after the normal hours of work for night traders. There are some interesting news to digest, and at least some moving actions as a result.

What are these companies? Keep reading to find out.

More

Source of the image: Getty Images.

Illumina cuts its annual goal

<p class = "web-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Actions of the DNA sequencing company Illumina (NASDAQ: ILMN) really takes on the chin tonight. After the market closed, the company said its quarterly revenue would not meet expectations. She also cut her financial forecast for fiscal year 2019. "Data-reactid =" 26 "> Shares of the DNA sequencing company Illumina (NASDAQ: ILMN) really takes on the chin tonight. After the market closed, the company said its quarterly revenue would not meet expectations. He also cut his financial forecast for the 2019 fiscal year.

Illumina said its preliminary figures indicated that it would reserve $ 835 million for the second quarter, $ 50 million less than expected, although they are still higher than the $ 830 million in the second quarter of 2018. For the full year of 2019, the company estimates that its turnover will reach 6% more than the 2018 result of $ 3.3 billion; Previously, it was forecasting growth of 13% to 14%.

In the press release conveying this sad news, Illumina said Q2 revenue was lower than expected mainly due to sales that had not progressed as expected in the population genomics segment. He also highlighted "persistent weakness" with his efforts to communicate directly with the consumer, among other factors.

The company has tried to sound optimistic despite hindsight, saying "our preliminary analysis suggests that these challenges are transitory and do not reflect a global change in the fundamentals of our business."

It seems that investors do not believe society in words. Illumina shares are down 16% tonight compared to the closing price of the market.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The timing of this ad is not It has recently negotiated at its highest historic level, thanks to positive fundamentals and expected progress in its imminent acquisition of Pacific Biosciences. & nbsp; "data-reactid =" 31 "> The timing of this announcement is not ideal for the stock.It's recently traded at its highest historic level, thanks to positive fundamentals and the anticipated progress of its imminent acquisition of Pacific Biosciences.

Colgate-Palmolive: $ 1.7 billion purchase

<p class = "web-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Giant of consumer goods Colgate-Palmolive (NYSE: CL) will soon be a bigger asset. The company announced the conclusion of an agreement for the acquisition of the skincare business of French laboratories Filorga Cosmetics. "Data-reactid =" 33 "> Giant consumer goods Colgate-Palmolive (NYSE: CL) will soon be a bigger asset. The company announced the conclusion of an agreement for the acquisition of the skincare business of French Filorga Cosmetiques laboratories in France.

Colgate-Palmolive will pay 1.5 billion euros ($ 1.7 billion) for this activity. It will finance this through a combination of cash and debt.

Filorga offers a range of skincare products upscale and anti-aging. It is present worldwide and is particularly active in European countries such as France and Italy. It is also important in China.

The acquisition is part of Colgate-Palmolive's efforts to strengthen its presence in relatively high margin segments, such as pet nutrition and personal care.

"We are delighted that this acquisition adds to Colgate's portfolio a global strength in skin care, with strong growth and profitability, with the opportunity to generate continued growth through increased distribution and brand awareness," said Colgate in his release.

The acquisition of Filorga is subject to approval by the relevant regulatory authorities. Colgate-Palmolive expects to close in the third quarter. The company said it would probably have no impact on the profitability of the 2019 fiscal year.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "This might not have much impact on the investor feeling, either (although on the back of some recent good resultsthis has been largely positive this year). In post-market action, Colgate-Palmolive shares are down, but marginally. "Data-reactid =" 39 "> This could also have little impact on investor sentiment (although, based on recent good results, this has been largely positive this year) in Post-market action, Colgate-Palmolive shares are down, but marginally.

The story continues